TGFBR1 Haplotypes and Risk of Non―Small-Cell Lung Cancer

• Published in: Cancer research (Chicago, Ill.) Vol. 69; no. 17; pp. 7046 - 7052
• Main Authors: ZHE LEI, LIU, Reng-Yun, ZHANG, Hong-Tao, JUN ZHAO, ZEYI LIU, XIEFANG JIANG, WEIMING YOU, CHEN, Xiao-Feng, XIA LIU, KUI ZHANG, PASCHE, Boris
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.09.2009
• Subjects: Age Factors; Antineoplastic agents; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - genetics; Case-Control Studies; Female; Genetic Predisposition to Disease; Haplotypes; Humans; Introns; Linkage Disequilibrium; Lung Neoplasms - genetics; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Pneumology; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Protein-Serine-Threonine Kinases - genetics; Receptors, Transforming Growth Factor beta - genetics; Sex Factors; Tumors; Tumors of the respiratory system and mediastinum; Lung disease; Respiratory disease; Lung cancer; Risk factor; Bronchus disease; Transforming growth factor β receptor 1; Malignant tumor; non-small cell lung carcinoma; Haplotype; Cancer
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-08-4602

Transforming growth factor beta (TGF-beta) receptors are centrally involved in TGF-beta-mediated cell growth and differentiation and are frequently inactivated in non-small-cell lung cancer (NSCLC). Constitutively decreased type I TGF-beta receptor (TGFBR1) expression is emerging as a novel tumor-predisposing phenotype. The association of TGFBR1 haplotypes with risk for NSCLC has not yet been studied. We tested the hypothesis that single-nucleotide polymorphisms (SNP) and/or TGFBR1 haplotypes are associated with risk of NSCLC. We genotyped six TGFBR1 haplotype-tagging SNPs (htSNP) by PCR-RFLP assays and one htSNP by PCR-single-strand conformation polymorphism assay in two case-control studies. Case-control study 1 included 102 NSCLC patients and 104 healthy controls from Suzhou. Case-control study 2 included 131 patients with NSCLC and 133 healthy controls from Wuxi. Individuals included in both case-control studies were Han Chinese. Haplotypes were reconstructed according to the genotyping data and linkage disequilibrium status of these seven htSNPs. None of the htSNP was associated with NSCLC risk in either study. However, a four-marker CTGC haplotype was significantly more common among controls than among cases in both studies (P = 0.014 and P = 0.010, respectively), indicating that this haplotype is associated with decreased NSCLC risk {adjusted odds ratio [OR], 0.09 [95% confidence interval (95% CI), 0.01-0.61] and 0.11 [95% CI, 0.02-0.59], respectively}. Combined analysis of both studies shows a strong association of this four-marker haplotype with decreased NSCLC risk (adjusted OR, 0.11; 95% CI, 0.03-0.39). This is the first evidence of an association between a TGFBR1 haplotype and risk for NSCLC.